Penserra Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10K | Hold |
21
| – | – | ﹤0.01% | 909 |
|
|
2026
Q1 | $9K | Hold |
21
| – | – | ﹤0.01% | 884 |
|
|
2025
Q4 | $9K | Hold |
21
| – | – | ﹤0.01% | 860 |
|
|
2025
Q3 | $8K | Hold |
21
| – | – | ﹤0.01% | 855 |
|
|
2025
Q2 | $9K | Sell |
21
-105
| -83% | -$48.4K | ﹤0.01% | 830 |
|
|
2025
Q1 | $60K | Sell |
126
-548
| -81% | -$255K | ﹤0.01% | 833 |
|
|
2024
Q4 | $270K | Buy |
674
+653
| +3,110% | +$303K | ﹤0.01% | 687 |
|
|
2024
Q3 | $9K | Hold |
21
| – | – | ﹤0.01% | 899 |
|
|
2024
Q2 | $10K | Hold |
21
| – | – | ﹤0.01% | 934 |
|
|
2024
Q1 | $8K | Sell |
21
-1,685
| -99% | -$712K | ﹤0.01% | 944 |
|
|
2023
Q4 | $693K | Buy |
1,706
+164
| +11% | +$60.6K | 0.01% | 447 |
|
|
2023
Q3 | $535K | Sell |
1,542
-448
| -23% | -$157K | 0.01% | 488 |
|
|
2023
Q2 | $698K | Sell |
1,990
-101
| -5% | -$34K | 0.01% | 436 |
|
|
2023
Q1 | $657K | Buy |
2,091
+1,957
| +1,460% | +$587K | 0.01% | 444 |
|
|
2022
Q4 | $38K | Sell |
134
-12,471
| -99% | -$3.8M | ﹤0.01% | 919 |
|
|
2022
Q3 | $3.65M | Sell |
12,605
-3,094
| -20% | -$890K | 0.1% | 168 |
|
|
2022
Q2 | $4.42M | Sell |
15,699
-7,263
| -32% | -$1.94M | 0.12% | 164 |
|
|
2022
Q1 | $5.99M | Buy |
22,962
+22,836
| +18,124% | +$5.42M | 0.14% | 180 |
|
|
2021
Q4 | $27K | Buy |
126
+6
| +5% | +$1.17K | ﹤0.01% | 1186 |
|
|
2021
Q3 | $21K | Buy |
120
+30
| +33% | +$5.86K | ﹤0.01% | 1242 |
|
|
2021
Q2 | $18K | Buy |
+90
| New | +$18.8K | ﹤0.01% | 1177 |
|
|
2021
Q1 | – | Sell |
-4,278
| Closed | -$1.01M | – | 1149 |
|
|
2020
Q4 | $1.01M | Sell |
4,278
-9,449
| -69% | -$2.17M | 0.02% | 311 |
|
|
2020
Q3 | $3.73M | Sell |
13,727
-12,173
| -47% | -$3.36M | 0.14% | 153 |
|
|
2020
Q2 | $7.52M | Buy |
25,900
+24,550
| +1,819% | +$6.66M | 0.39% | 85 |
|
|
2020
Q1 | $366K | Buy |
+1,350
| New | +$310K | 0.02% | 371 |
|
|
2018
Q3 | – | Sell |
-13,005
| Closed | -$2.21M | – | 758 |
|
|
2018
Q2 | $2.21M | Buy |
+13,005
| New | +$2.02M | 0.14% | 113 |
|
|
2017
Q3 | – | Sell |
-10,353
| Closed | -$1.33M | – | 608 |
|
|
2017
Q2 | $1.33M | Buy |
+10,353
| New | +$1.25M | 0.48% | 57 |
|
|
2017
Q1 | – | Sell |
-218
| Closed | -$16K | – | 838 |
|
|
2016
Q4 | $16K | Buy |
218
+33
| +18% | +$2.69K | ﹤0.01% | 721 |
|
|
2016
Q3 | $16K | Buy |
185
+74
| +67% | +$6.99K | ﹤0.01% | 690 |
|
|
2016
Q2 | $10K | Buy |
111
+42
| +61% | +$3.63K | ﹤0.01% | 690 |
|
|
2016
Q1 | $5 | Buy |
69
+17
| +33% | +$1.54K | ﹤0.01% | 853 |
|
|
2015
Q4 | $7K | Buy |
+52
| New | +$6.28K | ﹤0.01% | 661 |
|
Other funds holding VRTX
Penserra Capital Management's VRTX Position: Q2 2026 in Review
Penserra Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 21 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #909.
Penserra Capital Management first reported a position in VRTX in Q4 2015 and has held it in 32 quarters since. The position peaked at $7.52M in Q2 2020. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Penserra Capital Management held 21 shares of Vertex Pharmaceuticals worth $10K as of Q2 2026.
- Penserra Capital Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
- Vertex Pharmaceuticals made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #909 holding.
- Penserra Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 32 quarters since.
- Penserra Capital Management's Vertex Pharmaceuticals position peaked at $7.52M in Q2 2020.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.